We are live on
!
Find out more
6CM
683 Capital Management Portfolio holdings
AUM
$1.92B
1-Year Est. Return
85.52%
This Fund
S&P 500
This Quarter
Est. Return
+21.28%
1 Year Est. Return
+85.52%
3 Year Est. Return
+282.16%
5 Year Est. Return
+254.87%
10 Year Est. Return
+3,288.81%
AUM
$2.3B
AUM Growth
+$384M
(+20%)
Cap. Flow
+$216M
Cap. Flow
% of AUM
9.39%
Top 10 Holdings %
Top 10 Hldgs %
49.4%
Holding
255
New
116
Increased
33
Reduced
43
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kaspi.kz JSC
KSPI
|
+$20M |
| 2 |
MREO
Mereo BioPharma
MREO
|
+$19.3M |
| 3 |
Becton Dickinson
BDX
|
+$17.1M |
| 4 |
SUNC
SunocoCorp LLC
SUNC
|
+$11.8M |
| 5 |
Molina Healthcare
MOH
|
+$8.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Western Digital
WDC
|
+$29.7M |
| 2 |
uniQure
QURE
|
+$26.4M |
| 3 |
Eli Lilly
LLY
|
+$21.8M |
| 4 |
BridgeBio Pharma
BBIO
|
+$19.6M |
| 5 |
SNDK
Sandisk
SNDK
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.71% |
| 2 | Financials | 6.94% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Industrials | 3.7% |
| 5 | Technology | 3.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HDSN
101
Hudson Technologies
HDSN
$259M
| $2.29M | 0.1% |
335,000
-15,000
| -4% | -$118K |
|
102
MasterBrand
MBC
$1.17B
| $2.21M | 0.1% |
200,000
| – | – |
|
103
Cartesian Therapeutics
RNAC
$243M
| $2.02M | 0.09% |
280,000
+50,000
| +22% | +$404K |
|
|
CHEC
104
Chenghe Acquisition III Co
CHEC
$176M
| $1.99M | 0.09% |
+200,000
| New | +$1.99M |
|
|
AMRZ
105
Amrize Ltd
AMRZ
$29.2B
| $1.89M | 0.08% |
35,000
| – | – |
|
106
Valaris
VAL
$5.31B
| $1.76M | 0.08% |
35,000
| – | – |
|
107
PUT
Kenvue
KVUE
$37.4B
| $1.73M | 0.08% |
+100,000
| New | +$1.63M |
|
108
IN8bio
INAB
$9.51M
| $1.7M | 0.07% |
+724,637
| New | +$1.38M |
|
|
SVM
109
Silvercorp Metals
SVM
$2.38B
| $1.67M | 0.07% |
200,000
-125,000
| -38% | -$908K |
|
110
Cardlytics
CDLX
$23.8M
| $1.61M | 0.07% |
140,010
+22,510
| +19% | +$348K |
|
|
BLUW
111
Blue Water Acquisition Corp III
BLUW
$335M
| $1.55M | 0.07% |
150,000
| – | – |
|
112
Hyliion Holdings
HYLN
$726M
| $1.52M | 0.07% |
825,000
| – | – |
|
|
EVAC
113
EQV Ventures Acquisition Corp II
EVAC
$600M
| $1.5M | 0.07% |
150,000
| – | – |
|
114
Alnylam Pharmaceuticals
ALNY
$30.6B
| $1.5M | 0.07% |
+3,782
| New | +$1.67M |
|
115
Lightpath Technologies
LPTH
$774M
| $1.44M | 0.06% |
+133,595
| New | +$1.08M |
|
116
Zura Bio
ZURA
$532M
| $1.36M | 0.06% |
+259,165
| New | +$1.02M |
|
117
AXT Inc
AXTI
$4.78B
| $1.23M | 0.05% |
+75,000
| New | +$724K |
|
118
PepGen
PEPG
$135M
| $1.22M | 0.05% |
+186,916
| New | +$970K |
|
119
Lantronix
LTRX
$266M
| $1.21M | 0.05% |
+206,398
| New | +$1.07M |
|
120
Duos Technologies
DUOT
$283M
| $1.2M | 0.05% |
+106,481
| New | +$999K |
|
121
Hycroft Mining Holding Corp
HYMC
$2.29B
| $1.19M | 0.05% |
+50,000
| New | +$553K |
|
|
RSVR
122
Reservoir Media
RSVR
$664M
| $1.19M | 0.05% |
+156,954
| New | +$1.18M |
|
123
Prenetics Global
PRE
$316M
| $1.18M | 0.05% |
+75,000
| New | +$1.09M |
|
124
Alto Neuroscience
ANRO
$1.09B
| $1.15M | 0.05% |
+64,782
| New | +$816K |
|
125
Owlet
OWLT
$157M
| $1.13M | 0.05% |
+70,000
| New | +$793K |
|
Similar funds
QOP
RIL
MC
RCAG
BOH
DCM
CC
IAN
683 Capital Management's Q4 2025 Portfolio in Review
As of Q4 2025, 683 Capital Management held 255 positions worth $2.3B, up 20% from $1.91B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
683 Capital Management deployed $216M of net new capital in Q4 2025, opening 116 new positions and adding to 33 existing holdings. Its largest new stake was Kaspi.kz JSC: 265,000 shares worth $20.7M.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 23% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Western Digital, an estimated $29.7M trimmed.
- 683 Capital Management's largest Q4 2025 buy was Kaspi.kz JSC: 265,000 shares worth $20.7M.
- 683 Capital Management added most to Mereo BioPharma in Q4 2025, an estimated $19.3M increase.
- 683 Capital Management's biggest Q4 2025 reduction was Western Digital, cutting an estimated $29.7M.
- 683 Capital Management fully exited Eli Lilly in Q4 2025, selling an estimated $21.8M.
- 683 Capital Management's ten largest holdings make up 49% of its $2.3B portfolio in Q4 2025.
- 683 Capital Management opened 116 new positions and closed 21 in Q4 2025.
- 683 Capital Management's portfolio value rose 20% quarter-over-quarter to $2.3B.
Based on 683 Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.